DE69424545D1 - Verfahren zur herstellung von immunoglobulin g konzentrat - Google Patents

Verfahren zur herstellung von immunoglobulin g konzentrat

Info

Publication number
DE69424545D1
DE69424545D1 DE69424545T DE69424545T DE69424545D1 DE 69424545 D1 DE69424545 D1 DE 69424545D1 DE 69424545 T DE69424545 T DE 69424545T DE 69424545 T DE69424545 T DE 69424545T DE 69424545 D1 DE69424545 D1 DE 69424545D1
Authority
DE
Germany
Prior art keywords
concentrate
pct
immunoglobulin
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69424545T
Other languages
English (en)
Other versions
DE69424545T2 (de
Inventor
Miryana Burnouf
Dominique Dernis
Patrick Bonneel
Thierry Burnouf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
ASSOCIATION POUR L'ESSOR de la TRANSFUSION SANGUINE DANS LA REGION DU NORD LILLE
AETSRN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASSOCIATION POUR L'ESSOR de la TRANSFUSION SANGUINE DANS LA REGION DU NORD LILLE, AETSRN filed Critical ASSOCIATION POUR L'ESSOR de la TRANSFUSION SANGUINE DANS LA REGION DU NORD LILLE
Publication of DE69424545D1 publication Critical patent/DE69424545D1/de
Application granted granted Critical
Publication of DE69424545T2 publication Critical patent/DE69424545T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69424545T 1993-06-14 1994-06-13 Verfahren zur herstellung von immunoglobulin g konzentrat Expired - Lifetime DE69424545T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9307128A FR2706466B1 (fr) 1993-06-14 1993-06-14 Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
PCT/FR1994/000699 WO1994029334A1 (fr) 1993-06-14 1994-06-13 Concentre d'immunoglobulines g a usage therapeutique et procede de production dudit concentre

Publications (2)

Publication Number Publication Date
DE69424545D1 true DE69424545D1 (de) 2000-06-21
DE69424545T2 DE69424545T2 (de) 2001-01-18

Family

ID=9448094

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69424545T Expired - Lifetime DE69424545T2 (de) 1993-06-14 1994-06-13 Verfahren zur herstellung von immunoglobulin g konzentrat

Country Status (16)

Country Link
US (1) US6069236A (de)
EP (1) EP0703922B1 (de)
JP (1) JP4218980B2 (de)
AT (1) ATE193020T1 (de)
AU (1) AU7002394A (de)
BR (1) BR9406814A (de)
CA (1) CA2165203C (de)
CZ (1) CZ287186B6 (de)
DE (1) DE69424545T2 (de)
DK (1) DK0703922T3 (de)
ES (1) ES2148332T3 (de)
FR (1) FR2706466B1 (de)
GR (1) GR3034177T3 (de)
HU (1) HU218463B (de)
PT (1) PT703922E (de)
WO (1) WO1994029334A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1084147T3 (da) * 1998-06-09 2004-10-25 Statens Seruminstitut Fremgangsmåde til fremstilling af immunglobuliner til administration og andre immunglobulinprodukter
ES2421736T3 (es) * 1998-06-09 2013-09-05 Csl Behring Ag Procedimiento para la preparación de inmunoglobulinas para administración intravenosa y otros productos inmunoglobulínicos
US6962700B1 (en) 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2544816A1 (en) 2003-11-08 2005-05-26 Prothera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP1532983A1 (de) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulinpräparationen mit erhöhter Stabilität
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
WO2007136327A1 (en) * 2006-05-22 2007-11-29 Ge Healthcare Bio-Sciences Ab A method of producing igg
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
PT2291654T (pt) 2008-05-28 2018-06-15 Prothera Biologics Inc Preparação e composição de proteínas inibidoras de interalfa do sangue
FR2939667B1 (fr) 2008-12-17 2012-01-27 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo
AU2010253830B2 (en) 2009-05-27 2016-03-03 Takeda Pharmaceutical Company Limited A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
JP5734985B2 (ja) 2009-09-17 2015-06-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
IT1397061B1 (it) 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
CA2817096A1 (en) 2010-11-16 2012-05-24 Octapharma Ag A process for reduction and/or removal of fxi and fxia from solutions containing said coagulation factors
JP6189751B2 (ja) 2010-12-30 2017-08-30 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 病原体不活性化剤としてのグリコール
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
ES2647925T3 (es) 2011-05-12 2017-12-27 Csl Behring Gmbh Métodos para reducir los eventos adversos causados por preparados farmacéuticos que comprenden proteínas derivadas del plasma
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
US9403899B2 (en) 2011-08-26 2016-08-02 Baxalta Incorporated Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
FI3590960T3 (fi) 2012-02-29 2023-04-25 Takeda Pharmaceuticals Co Perifeeristen hermojen IgG-stimuloitu remyelinaatio
MX360245B (es) 2012-03-09 2018-10-26 Csl Behring Ag Composiciones que comprenden inmunoglobulinas de tipo secretor.
EP2636681A1 (de) 2012-03-09 2013-09-11 CSL Behring AG Verfahren zur Anreicherung von IgA
EP2636684A1 (de) 2012-03-09 2013-09-11 CSL Behring AG Vorbeugung von Infektionen
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
CN105358228A (zh) * 2013-07-05 2016-02-24 法国血液分割暨生化制品实验室 亲和层析基质
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
CN106459140B (zh) * 2014-03-11 2019-12-10 株式会社绿十字控股 用于纯化免疫球蛋白的方法
FR3018450B1 (fr) 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines
US9556253B2 (en) * 2014-12-02 2017-01-31 Hemarus Therapeutics Limited Process for increased yield of immunoglobulin from human plasma
FR3064486A1 (fr) 2017-03-31 2018-10-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Prevention d'une infection par le virus respiratoire syncytial dans les voies respiratoires superieures
FR3064484A1 (fr) 2017-03-31 2018-10-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition d'immunoglobulines utiles pour traiter des infections virales
FR3064485A1 (fr) 2017-03-31 2018-10-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Traitement d'une infection par le virus respiratoire syncytial
BR112022019074A2 (pt) 2020-03-31 2022-11-29 Takeda Pharmaceuticals Co Método para preparar uma fração enriquecida com imunoglobulina g (igg), sobrenadante após a fração de adsorção do inibidor de c1 compreendendo igg, e, composição farmacêutica
KR20230125282A (ko) * 2020-12-28 2023-08-29 플라즈마 테크놀로지스, 엘엘씨 면역글로불린 G의 공정 규모 단리를 위한 시스템 및방법 (Systems and Methods for Process Scale Isolation of Immunoglobulin G)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7511055A (nl) * 1975-09-19 1977-03-22 Leuven Res & Dev Vzw Trombosetest.
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
ES502788A0 (es) * 1981-06-04 1982-04-01 Landerlan Sa Lab Procedimiento de preparacion de imuno globulina g nativa li-bre de actividad anticomplementaria
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4841024A (en) * 1986-09-15 1989-06-20 Becton Dickinson And Company Purification of antibodies
DE3640513A1 (de) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
DE3641115A1 (de) * 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
US4806346A (en) * 1986-12-16 1989-02-21 American Home Products Corporation Method for isolation of antigen specific immunoglobulin
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
DE4118912C1 (de) * 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
HU218463B (hu) 2000-09-28
HU9503557D0 (en) 1996-02-28
CA2165203C (fr) 2009-08-18
US6069236A (en) 2000-05-30
CA2165203A1 (fr) 1994-12-22
HUT74272A (en) 1996-11-28
GR3034177T3 (en) 2000-11-30
EP0703922B1 (de) 2000-05-17
FR2706466B1 (fr) 1995-08-25
ATE193020T1 (de) 2000-06-15
PT703922E (pt) 2000-11-30
ES2148332T3 (es) 2000-10-16
CZ328795A3 (en) 1996-07-17
AU7002394A (en) 1995-01-03
CZ287186B6 (en) 2000-10-11
FR2706466A1 (fr) 1994-12-23
EP0703922A1 (de) 1996-04-03
DK0703922T3 (da) 2000-11-13
JPH09500369A (ja) 1997-01-14
BR9406814A (pt) 2000-05-30
WO1994029334A1 (fr) 1994-12-22
JP4218980B2 (ja) 2009-02-04
DE69424545T2 (de) 2001-01-18

Similar Documents

Publication Publication Date Title
ATE193020T1 (de) Verfahren zur herstellung von immunoglobulin g konzentrat
DE59305526D1 (de) Verfahren zur herstellung von olefinen
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
ATE288447T1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
ATE232854T1 (de) Verfahren zur herstellung von 9-desoxotaxanen
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ATE213252T1 (de) Verfahren zur herstellung eines inter-alpha- trypsin inhibitor konzentrats mit therapeutischer anwendung und so erhaltenes konzentrat
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
ATE218131T1 (de) Verfahren zur herstellung von mono-n- substituierten tetraazamakrocyclen
ATE236926T1 (de) Herstellung von immunglobulin
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
AU4876196A (en) A process for the preparation of factor ix from biological sources
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE152722T1 (de) Verfahren zur herstellung von 9-(2-hydroxy)- ethoxy-guanin
ATE171620T1 (de) Verwendung von verzweigtkettigen aminosäuren zur herstellung eines arzneimittels zur behandlung von tardiver dyskinesia
DE59603295D1 (de) Verfahren zur herstellung von dolastatin 15 und deren zwischenprodukten
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69514512T2 (de) Verfahren zur herstellung von benzopyranderivaten
ATE210665T1 (de) Zwischenprodukte und verfahren zur herstellung von 5,6-dihydropyrrolo(2,3-d)pyrimidinen
DE69414196T2 (de) Sulfat eines n-acetyleneuraminicsaurehomopolymers, verfahren zur herstellung, anti-hiv-droge enthaltend dieses sulfat, verfahren zur behandlung von aids mit diesem sulfat, verwendung dieses sulfats in der behandlung von aids und in der herstellung von medikamenten
ATE142188T1 (de) Verfahren zur reinigung von 1,1-dichlor-1- fluorethan
DE69625819D1 (de) Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: L'ETABLISSEMENT FRANCAIS DU SANG, LA PLAINE SA, FR

8328 Change in the person/name/address of the agent

Representative=s name: CABINET HIRSCH & ASSOCIES, PARIS, FR

8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR